Semaglutide-13C6,15N trifluoroacetic acid isotopes, is a form of Semaglutide trifluoroacetic acid. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide trifluoroacetic acid exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer.